Cases
Experience: Representative Matters: A startup focused on the discovery
development of transformative therapies for the unmet medical needs of cancer patients: IP, licensing,
corporate matters.
A biopharmaceutical company dedicated to the development of innovative anti-cancer metastasis
antiviral drugs: IP
corporate matters.
A company developing novel therapeutics based on gene editing, RNA editing,
delivery technology: IP
technology transactions.
A biotech venture capital positioned to rapidly translate scientific discoveries into innovative new medicines: China licensing matters.
A company pioneering transformation of cancer treatment by enabling CAR-T cancer therapies to work more effectively: various licensing
collaboration matters.
A medical device company dedicated to ending obesity: China collaboration.
A clinical-stage immuno-oncology company focused on the discovery
development of potential best-in-class antibody therapies for the treatment of patients with solid tumors
hematologic malignancies: China IP matters.
A biotechnology company developing antibody drug conjugates: China licensing dispute resolution.
A privately owned medical device company based in Silicon Valley, California, USA: China licensing matters.
A clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer: licensing dispute resolution.
A world leader in executing complex cell edits: various licensing transactions.
A company developing drugs that specifically target the tumor blood vessels of most solid tumors: corporate restructuring
China licensing matters.
A global, science-driven biotechnology company focused on developing innovative
affordable medicines to improve treatment outcomes
access for patients worldwide: various technology transactions.
The only biotech company in China with publicly declared focus to develop Treg immune therapy: patent, corporate,
technology transactions matters.
A preclinical stage biotherapeutics company developing cost-effective, non-invasive,
easily accessible technologies to cure lung disease
repair damaged lung tissue: sponsored research agreements.
A company discovering life-changing medicines
cures for people with viral
liver diseases: various technology transactions.
A medical device company committed to improving the experience of both patients
surgeons through innovative technologies: patent matters.
A biomedical company working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives: China collaboration.
An innovative drug research
development company that focuses on the field of cellular immunotherapy: various licensing matters.
A family-owned medical device company that works with physicians to develop devices that are less invasive for patients: China strategies.
A company developing
manufacturing proprietary interventional liquid nitrogen spray cryotherapy systems: financing from China.
A company developing energy devices for various aesthetic
dermatology treatments: China regulatory matters.
A developer of novel, coordinated immunotherapy solutions for patients: various licensing transactions.
A developer of custom diagnostic solutions with a focus on large-scale, global diagnostic needs including antibody, molecular,
antigen tests in traditional
non-traditional settings: China supply matters.
Eluminex Biosciences: various licensing
collaboration transactions, including: global exclusive license agreement with FibroGen, Inc. on biosynthetic cornea
other recombinant human collagen products.
acquisition of Zuretinol assets from Retinagenix Holdings.
A leader in OLED microdisplay technology for the next generation of computing
imaging devices: China distribution matters.
A discovery research company developing revolutionary treatments for patients with genetic disorders: general corporate, asset transfer, financing,
licensing,
services agreements.
A developer of EV charging software
hardware for forward-thinking companies around the world: development services agreement.
A consumer health
wellness products platform focused on better-for-you consumer health & personal care br
s
products: China patent
regulatory matters.
A biotech company that drives drug discovery on with AI: IP matters.
A pioneering vaccine company dedicated to developing innovative solutions for global health challenges: general corporate matters.
A medical research company to improve reproductive health care: China supply matters.
A biotechnology company developing innovative gene therapies
cell therapies that are affordable
therapeutically effective: various patent
licensing matters.
A developer of a differentiated pipeline of innovative antibody therapeutics that will potentially transform how cancers are treated: general corporate, IP, tax, cybersecurity, licensing,
dispute resolution matters.
The first company in China to use induced-pluripotent stem cells
mesenchymal stem cell technology to develop a new generation of universal cell therapy products to treat clinically incurable diseases: licensing
collaboration matters.
A global biopharmaceutical company with a focus on oncology, autoimmune diseases,
ophthalmic diseases: licensing
collaboration matters.
A medical device company capturing, promoting,
advancing the category of abdominal wall
pelvic floor health, using a multifaceted, gender-specific approach: consulting agreement
various collaboration matters.
A biopharmaceutical company engaged in discovery
development of novel cell therapies
biologics for oncology
autoimmune diseases: contract dispute resolution.
A biomedical research technology company dedicated to the development
application of tumor immunotherapy technology: licensing
collaboration matters.
A cancer therapeutics biotechnology company, located at LabCentral in Cambridge, Massachusetts: China collaboration.
A developer of mobile phototherapy systems: general corporate, regulatory,
trademark matters.
A global mRNA CDMO company headquartered in United States: patent strategies.
A pharmaceutical company developing innovative products of low regulatory risks
high market potentials: financing
regulatory matters.
A leading eClinical provider: China human genetic resources regulatory advice.
A bio-pharma company spun out from Stanford University
focusing on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human
companion animals: IP
technology transactions.
A biotechnology company specializing in the development of advanced therapeutic antibodies, particularly focused on neurodegenerative diseases such as Alzheimer's disease: general corporate matters.
A next-generation biotech company specializing in computational drug design for innovative therapeutics: IP
licensing matters.
A company that has nearly $10 billion in public equities, primarily in the technology sector: China IP due diligence.
A pharmaceutical company using cutting-edge tools to make therapeutic progress against the most challenging of targets: sale of a subsidiary.
A strategy software provider: IP matters.
A private, Canada-based biotech company focused on neuroscience therapeutics: technology transactions.
A high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs: various collaborations.
A company developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes: various collaborations.
A biotechnology company headquartered in China's Eye Valley: various licensing
collaboration matters.
A health care company pioneering the field of integrated diagnostics: China contract dispute resolution
subsidiary China data transfer matters.
A leading Chinese company in gene therapies based on gene editing: IP, licensing,
financing matters.
A company specializing in international investment
financing, market access consulting, import-export trade, market promotion, sales, production outsourcing,
global procurement services in the biopharmaceutical
medical device industries: general corporate matters.
A company that pioneers innovative therapies for cancer, genetic diseases,
autoimmune diseases: IP
various licensing
collaboration matters.
A leading antibody discovery service provider with a pioneering platform that can accelerate the process
capture all available data: general corporate
IP matters.
A pioneer in discovering the mRNA-dependent DNA repair pathway
developing next-gen treatment for cancer treatment: general corporate, financing,
collaboration matters.
A provider of a single integrated cloud-based management console: China IP dispute resolution matters.
A China-based, global-oriented R&D company focusing on innovative drugs for diseases in the field of nervous system
autoimmunity: various licensing
collaboration matters.
A high-tech biotechnology company co-founded by overseas experts, returnee scientists
local Chinese pharmaceutical entrepreneurs: various licensing, collaboration
financing matters, including collaboration with
investment by a global, science-led, patient-focused pharmaceutical company.
A privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival: general corporate, IP,
licensing matters.
A biologically-targeted radiation therapy company focused on developing novel treatment to improve the lives of patients with difficult-to-treat cancers: various distribution, license,
collaboration transactions, including with South Korean
Japanese collaborators.
A rapidly developing company primarily engaged in the production of heat sinks, fans,
related products: IP matters.
A company engaged in research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate
collaboration matters.
A company developing a technology that combines the noninvasive diffuse reflectance spectroscopy with patented algorithms for detecting various skin properties
body health condition: various licensing transactions.
A company active in the field of research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate
licensing matters.
A company developing multiple new medical technologies to treat various metabolic diseases, such as obesity, type 2 diabetes,
nonalcoholic fatty liver: collaboration matters.
Vazyme Biotech Co., Ltd: IP transactions
product distribution matters.
A company focused on R&D of innovative mRNA drugs
adjuvants: patent, technology transactions,
global trade matters.
A company building computer aided diagnosis algorithms
systems in clinical imaging to improve diagnostic accuracy
effectiveness: various distribution
collaboration matters.
A technology innovator with an integrated platform that accelerates biopharmaceutical research: collaboration matters.
A provider of new drug c
idates through structure-based de novo drug design to accelerate drug discovery: various licensing
collaboration matters.
A Chinese national high-tech enterprise specializing in the research
industrialization of innovative drugs: various IP
technology transactions matters.
The above representations were h
led by Dr. Cui prior to his joining Greenberg Traurig, LLP.
Teaching Experience: Adjunct Faculty Member, The Chinese University of Hong Kong Faculty of Law, 2013-2016.
Guest Lecturer, Santa Clara University School of Law, 2022-present.
